Mesoblast (MESO) Non Operating Income (2018 - 2019)

Mesoblast (MESO) posted Non Operating Income of -$2.8 million for Q1 2019, down 554.37% sequentially from -$423000.0 in Q1 2018, and down 554.37% YoY from $609190.4 in Q1 2018.

Mesoblast (MESO) Non Operating Income (2018 - 2019) Analysis & Trends

Mesoblast has reported Non Operating Income for 2 years, with the latest figure at -$2.8 million in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 234.30 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -139.24 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 12.40
7 Royalty Pharma 33.72 Bn 35.84 Bn - -51.63 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -53.64 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Mesoblast 2.01 Bn 1.87 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2019 -2.77 Mn
Mar 31, 2018 -423,000.00